Across TCGA pan-cancer cohorts, CLUAP1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CLUAP1 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CLUAP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLUAP1 expression acts as an unfavorable survival marker.
CESC, LIHC, and UCEC are the cancer types where CLUAP1 Mutation most reproducibly stratifies survival.